Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q1 2026 · 10-Q
Revenue$4.02M$4.02M+18.4% vs Q1 2025 Net Income-$1.24M-$1.24MN/M vs Q1 2025 EPS Diluted-$0.76-$0.76N/M vs Q1 2025 Gross Profit$1,464,000+12.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flow-$2,015,000N/M Free Cash Flowderived-$2,121,000N/M Margins · derivedGross margin36.5%−2.1 pt vs Q1 2025
Operating margin-27.3%+7.3 pt vs Q1 2025
Net margin-30.9%+2.8 pt vs Q1 2025
ended Jun 30, 2025 · filed Aug 7, 2025 · 38 d after period end